During the past decade, Gundersen Health System conducted 33 clinical trials. In the 10-year time frame, 33 clinical trials started and 20 clinical trials were completed, i.e. on average, 60.6% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 11 clinical trials were completed. i.e. 84.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gundersen Health System" #1 sponsor was "Gundersen Lutheran Medical Foundation" with 9 trials, followed by "PrECOG, LLC." with 6 trials sponsored, "Human Genome Sciences Inc." with 3 trials sponsored, "Jaeb Center for Health Research" with 3 trials sponsored and "Bristol-Myers Squibb" with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gundersen Health System" #1 collaborator was "Gundersen Lutheran Health System" with 6 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 5 trials as a collaborator, "Massachusetts General Hospital" with 4 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator and "National Cancer Institute (NCI)" with 3 trials as a collaborator. Other collaborators include 139 different institutions and companies that were collaborators in the rest 135 trials.

According to Clinical.Site data, the most researched conditions in "Gundersen Health System" are "Multiple Myeloma" (4 trials), "Cancer" (2 trials), "Coronary Artery Disease" (2 trials), "Deep Vein Thrombosis" (2 trials) and "Lymphoma" (2 trials). Many other conditions were trialed in "Gundersen Health System" in a lesser frequency.

Most popular intervention types in "Gundersen Health System" are "Drug" (33 trials), "Device" (13 trials), "Other" (7 trials), "Procedure" (7 trials) and "Biological" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Dexamethasone" (4 trials), "Lenalidomide" (4 trials), "Aspirin" (2 trials) and "Belimumab 1 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Gundersen Health System" are 57 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Gundersen Health System". undefined are not yet recruiting, 11 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Gundersen Health System, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Gundersen Health System, 3 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 15 trials that are defined as “Not Applicable".